Dissolved and financials
CVR: 38663062
DKK -1,415
Gross profit
Net result: DKK -1,415
No owners listed
CVR · view owners
No current management
CVR · view management
Dissolved
Ceased 15 January 2020
CVR · view overview
0 employees
Annual report 2018 · average
Director role ended: Steven Alan Goldman
CVR · 15/01/2020
View the full event history
Oscine Therapeutics IVS was a Danish company of the type Iværksætterselskab based in København N, founded in 2017. The company has been dissolved on 15 January 2020. The company was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi. According to the 2018 annual report, the company had an average of 0 employees. In 2018, the company reported a gross profit of DKK -1,415 and a net result of DKK -1,415. Equity in the 2018 report amounted to DKK 5,585.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 201801/01/2018 – 31/12/2018 | -1K | -1K | 7K | 6K | 0 |
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreNo. Oscine Therapeutics IVS is registered in the Danish CVR register with the status Dissolved and ceased on 15 January 2020.
The CVR number of Oscine Therapeutics IVS is 38663062.
In 2018, Oscine Therapeutics IVS reported a gross profit of DKK -1,415.
Oscine Therapeutics IVS had an average of 0 employees in the 2018 financial year according to the annual report.
Oscine Therapeutics IVS was founded on 24 May 2017.
Oscine Therapeutics IVS was registered under the industry Forskning og eksperimentel udvikling indenfor bioteknologi (industry code 721100).
As of January 15, 2020, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of Oscine Therapeutics IVS.
As of January 15, 2020, Steven Alan Goldman has stepped down as chairman of Oscine Therapeutics IVS.
As of January 15, 2020, Christina Trojel-Hansen has stepped down as director of Oscine Therapeutics IVS.
Oscine Therapeutics IVS was dissolved on January 15, 2020.
Oscine Therapeutics IVS has published its annual report for 2018. Gross profit came to DKK -1,415, and the net result was DKK -1,415.
Oscine Therapeutics IVS has published its interim report for the period May 24, 2017 to December 31, 2017.
As of March 22, 2018, Steven Alan Goldman is registered as chairman of Oscine Therapeutics IVS.
As of March 22, 2018, Christina Trojel-Hansen is registered as director of Oscine Therapeutics IVS.
As of March 22, 2018, Steven Alan Goldman has stepped down as director of Oscine Therapeutics IVS.
As of May 24, 2017, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of Oscine Therapeutics IVS.
As of May 24, 2017, Steven Alan Goldman is registered as director of Oscine Therapeutics IVS.
Oscine Therapeutics IVS was founded on May 24, 2017.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
